Abstract
Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Cardiovascular & Hematological Disorders-Drug Targets
Title: Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds
Volume: 11 Issue: 2
Author(s): F. A. Syed, J. H.N. Bett and D. L. Walters
Affiliation:
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Abstract: Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Export Options
About this article
Cite this article as:
A. Syed F., H.N. Bett J. and L. Walters D., Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152911798347007
DOI https://dx.doi.org/10.2174/187152911798347007 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD
Current Alzheimer Research Cardiac Response to Exercise in Normal Ageing: What Can We Learn from Masters Athletes?
Current Cardiology Reviews Matrix Metalloproteinases in Venous Tissue Remodeling and Varicose Vein Formation
Current Vascular Pharmacology Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Primary Hyperaldosteronism in the Hypertensive Disease
Current Hypertension Reviews Substance P in Rheumatic Diseases
Current Rheumatology Reviews Stem Cells in Adult Human Ovaries: From Female Fertility to Ovarian Cancer
Current Pharmaceutical Design The Renin-Angiotensin System: The Role of Inhibitors, Blockers, and Genetic Polymorphisms in the Treatment and Prevention of Heart Failure
Current Vascular Pharmacology Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Integrated Quality by Design (QbD) Approach for Stability Indicating RPHPLC Method for the Estimation of Tadalafil Hydrochloride in Bulk Drug and Pharmaceutical Formulations
Current Pharmaceutical Analysis Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions
Cardiovascular & Hematological Disorders-Drug Targets Progress and Survey of Mobile Image Feature Recognition
Recent Patents on Computer Science Activated Protein C: A Promising Drug with Multiple Effects?
Mini-Reviews in Medicinal Chemistry A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews The Role of Coffee and its Bioactive Components in Platelet Function and Aging
Mini-Reviews in Medicinal Chemistry Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Efficacy of Vitamins B Supplementation on Mild Cognitive Impairment and Alzheimer`s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology